Latest News for: seres

Edit

Petri Dish: Flagship spinout raises $65M; Seres medical chief lands new role

Business Journal 20 Mar 2025
This past week saw a Flagship spinout secure a Series B round, while Insilico Medicine raised a late-stage financing of over $100 million. And, we finally know what local biotech the former medical chief of Seres Therapeutics is joining ... .
Edit

Vuelos de inmigración de EEUU desatan búsquedas internacionales por seres queridos desaparecidos

San Diego Union-Tribune 19 Mar 2025
Franco Caraballo llamó a su esposa el viernes por la noche, llorando y en pánico ... No tenía idea de a dónde iba ... Sánchez insiste en que su esposo no es un miembro de una pandilla ... Pero muchas familias no tienen idea de dónde buscar a sus seres queridos ... .
Edit

Corporate Presentation – March 2025 (Seres Therapeutics Inc)

Public Technologies 13 Mar 2025
). Pioneering mRNA Cell Therapy for Autoimmunity. March 2025. MULTIPLE ANTICIPATED NEAR-TERM CATALYSTS. Clinical-stage company pioneering mRNA cell therapies designed. to expand the reach of cell therapy to autoimmunity ... 3 ... 4 ... Asset ... 5 ... Seres Therapeutics Inc.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Seres Therapeutics Inc)

Public Technologies 13 Mar 2025
SERES THERAPEUTICS, INC ... Seres Therapeutics, Inc ... Seres Therapeutics, Inc ... Seres Therapeutics, Inc ... (the “Registrant”) to be issued pursuant to the Seres Therapeutics, Inc ... 99.1 Seres Therapeutics, Inc ... 99.2 Seres Therapeutics, Inc ... SERES THERAPEUTICS, INC.
Edit

SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES (Form 8-K) (Seres Therapeutics Inc)

Public Technologies 13 Mar 2025
SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 ... operating plans, Seres expects to fund operations into Q1 2026 ... CAMBRIDGE, Mass.-March 13, 2025 - Seres Therapeutics, Inc ... About Seres Therapeutics. Seres Therapeutics, Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) (Seres Therapeutics Inc)

Public Technologies 13 Mar 2025
The license from Seres to SPN is to issued Seres patents that currently or in the future cover the Product or improvements thereof and know-how that is used or reasonably useful in connection with the exploitation of the VOWST Business.
Edit

Proxy Statement (Form DEF 14A) (Seres Therapeutics Inc)

Public Technologies 13 Mar 2025
SERES THERAPEUTICS, INC ... Seres Therapeutics, Inc ... SERES THERAPEUTICS, INC ... You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Seres Therapeutics, Inc ... Approval of the Seres Therapeutics, Inc ... Seres' Annual Report on Form 10-K.
Edit

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Nasdaq Globe Newswire 03 Mar 2025
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study ... .
Edit

Preliminary Proxy Statement (Form PRE 14A) (Seres Therapeutics Inc)

Public Technologies 03 Mar 2025
SERES THERAPEUTICS, INC ... Seres Therapeutics, Inc ... SERES THERAPEUTICS, INC ... You are cordially invited to attend the 2025 Annual Meeting of Stockholders of Seres Therapeutics, Inc ... Approval of the Seres Therapeutics, Inc ... Seres' Annual Report on Form 10-K.
  • 1
×